JPH06504903A - レニラ(renilla)ルシフェラーゼのクローニング及び発現 - Google Patents
レニラ(renilla)ルシフェラーゼのクローニング及び発現Info
- Publication number
- JPH06504903A JPH06504903A JP3506544A JP50654491A JPH06504903A JP H06504903 A JPH06504903 A JP H06504903A JP 3506544 A JP3506544 A JP 3506544A JP 50654491 A JP50654491 A JP 50654491A JP H06504903 A JPH06504903 A JP H06504903A
- Authority
- JP
- Japan
- Prior art keywords
- luciferase
- sequence
- dna
- molecule
- renilla
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0069—Oxidoreductases (1.) acting on single donors with incorporation of molecular oxygen, i.e. oxygenases (1.13)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y113/00—Oxidoreductases acting on single donors with incorporation of molecular oxygen (oxygenases) (1.13)
- C12Y113/12—Oxidoreductases acting on single donors with incorporation of molecular oxygen (oxygenases) (1.13) with incorporation of one atom of oxygen (internal monooxygenases or internal mixed function oxidases)(1.13.12)
- C12Y113/12005—Renilla-luciferin 2-monooxygenase (1.13.12.5), i.e. renilla-luciferase
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
Claims (17)
- 1.レニラルシフェラーゼをコードするヌクレオチド配列を含む単離DNA又は RNA分子。
- 2.該分子がルシフェラーゼコード配列:【配列があります】 を含む、請求の範囲1に記載の分子又は同等DNAあるいはRNA配列。
- 3.該分子がDNAである、請求の範囲2に記載の分子。
- 4.該分子が該ルシフェラーゼ配列を含む、請求の範囲3に記載の分子。
- 5.該分子がRNAであり、該ルシフェラーゼ配列と同等の配列を含む、請求の 範囲2に記載の分子。
- 6.該配列の前に機能的プロモーター配列5′がある、請求の範囲1に記載の分 子。
- 7.該配列の少なくとも1個のコピーが組み替えDNA又はRNAベクター中に 存在する、請求の範囲6に記載の分子。
- 8.請求の範囲7に記載のベクターを含む、遺伝的操作された微生物。
- 9.該微生物がE.coli株である、請求の範囲8に記載の微生物。
- 10.ヌクレオチド配列: 【配列があります】 相補的DNA配列、及び同等又は相補的RNA配列から選ばれる少なくとも10 個の連続したヌクレオチドを含む単離オリゴヌクレオチド。
- 11.該オリゴヌクレオチドが検出可能なタグで標識されている、請求の範囲1 0に記載のオリゴヌクレオチド。
- 12.該オリゴヌクレオチドが少なくとも14個の連続したヌクレオチドを含む 、請求の範囲10に記載のオリゴヌクレオチド。
- 13.腔腸動物から遺伝物質を単離して遺伝物質の試料を形成し、該試料をハイ ブリッド形成条件下で請求の範囲10に記載のオリゴヌクレオチドと接触させ、 該オリゴヌクレオチド及び該試料中に存在するDNA又はRNAを含む二重らせ んの形成を検出する段階を含む、腔腸動物ルシフェラーゼ遺伝子をコードする遺 伝物質の同定法。
- 14.該方法がポリメラーゼ連鎖反応を含む、請求の範囲13に記載の方法。
- 15.請求の範囲1に記載のヌクレオチド配列によりコードされる遺伝的操作さ れたペプチド。
- 16.該ペプチドが非−グリコシル化である、請求の範囲15に記載のペプチド 。
- 17.図3のアミノ酸配列、又は少なくとも5個の連続したアミノ酸残基を含み 、レニラルシフェラーゼと特異的に結合する抗体と免疫学的に反応性である該配 列のフラグメントを含み、他のレニラペプチドを含まないペプチド。
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US1991/001614 WO1992015673A1 (en) | 1991-03-11 | 1991-03-11 | Cloning and expression of renilla luciferase |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH06504903A true JPH06504903A (ja) | 1994-06-09 |
JP3126980B2 JP3126980B2 (ja) | 2001-01-22 |
Family
ID=22225386
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP03506544A Expired - Lifetime JP3126980B2 (ja) | 1991-03-11 | 1991-03-11 | レニラ(renilla)ルシフェラーゼのクローニング及び発現 |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP0575319B1 (ja) |
JP (1) | JP3126980B2 (ja) |
CA (1) | CA2105984C (ja) |
DE (1) | DE69131780T2 (ja) |
DK (1) | DK0575319T3 (ja) |
ES (1) | ES2142801T3 (ja) |
GR (1) | GR3032608T3 (ja) |
WO (1) | WO1992015673A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002507410A (ja) * | 1998-03-27 | 2002-03-12 | プロルーム・リミテッド | ルシフェラーゼ、蛍光タンパク質、ルシフェラーゼおよび蛍光タンパク質をコードする核酸および、診断、高処理スクリーニングおよび新規アイテムにおけるその使用 |
Families Citing this family (122)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE60117761T2 (de) * | 2000-03-15 | 2006-08-31 | Prolume, Ltd. | Luciferase, Fluoreszenzproteine, für Luciferase und Fluoreszenzproteine Kodierend Nukleinsäure und ihre Verwendung in der Diagnose, Hoch-Durchsatz Screeningsverfahren |
JP3927809B2 (ja) * | 2000-04-17 | 2007-06-13 | ローマ リンダ ユニバーシティー | 糖尿病を予防し又は治療する方法 |
US7879540B1 (en) | 2000-08-24 | 2011-02-01 | Promega Corporation | Synthetic nucleic acid molecule compositions and methods of preparation |
US7393656B2 (en) | 2001-07-10 | 2008-07-01 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for risk stratification |
US9453251B2 (en) | 2002-10-08 | 2016-09-27 | Pfenex Inc. | Expression of mammalian proteins in Pseudomonas fluorescens |
US8399618B2 (en) | 2004-10-21 | 2013-03-19 | Xencor, Inc. | Immunoglobulin insertions, deletions, and substitutions |
US8883147B2 (en) | 2004-10-21 | 2014-11-11 | Xencor, Inc. | Immunoglobulins insertions, deletions, and substitutions |
US7481997B1 (en) | 2004-02-12 | 2009-01-27 | Montana State University | Snow mountain virus genome sequence, virus-like particles and methods of use |
AU2005269527B2 (en) | 2004-07-26 | 2011-12-01 | Pfenex Inc. | Process for improved protein expression by strain engineering |
US7728118B2 (en) | 2004-09-17 | 2010-06-01 | Promega Corporation | Synthetic nucleic acid molecule compositions and methods of preparation |
CA2587617C (en) | 2004-11-12 | 2011-02-01 | Xencor, Inc. | Fc variants with altered binding to fcrn |
US8802820B2 (en) | 2004-11-12 | 2014-08-12 | Xencor, Inc. | Fc variants with altered binding to FcRn |
US8227572B2 (en) | 2005-08-19 | 2012-07-24 | Commonwealth Scientific And Industrial Research Organisation | Arachnocampa luciferases |
EP2442108B1 (en) | 2006-07-14 | 2016-11-16 | The Regents of The University of California | Cancer biomarkers and methods of use thereof |
US7833527B2 (en) | 2006-10-02 | 2010-11-16 | Amgen Inc. | Methods of treating psoriasis using IL-17 Receptor A antibodies |
JP5444553B2 (ja) | 2007-04-27 | 2014-03-19 | フェネックス インコーポレイテッド | 微生物宿主を迅速にスクリーニングして、異種タンパク質発現の収率および/または質が改善されている特定の株を同定する方法 |
US9580719B2 (en) | 2007-04-27 | 2017-02-28 | Pfenex, Inc. | Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins |
JP2010536371A (ja) | 2007-08-21 | 2010-12-02 | ノダリティ,インコーポレイテッド | 診断方法、予後および治療方法 |
CA2696761C (en) | 2007-08-21 | 2017-02-14 | Amgen Inc. | Human c-fms antigen binding proteins |
TW200918553A (en) | 2007-09-18 | 2009-05-01 | Amgen Inc | Human GM-CSF antigen binding proteins |
JP5511669B2 (ja) | 2007-10-02 | 2014-06-04 | セラノス, インコーポレイテッド | モジュール式ポイントオブケアデバイスおよびその使用 |
CA3086659A1 (en) | 2007-12-26 | 2009-07-09 | Xencor, Inc. | Fc variants with altered binding to fcrn |
US8309306B2 (en) | 2008-11-12 | 2012-11-13 | Nodality, Inc. | Detection composition |
JO3382B1 (ar) | 2008-12-23 | 2019-03-13 | Amgen Inc | أجسام مضادة ترتبط مع مستقبل cgrp بشري |
US8242248B2 (en) | 2009-03-23 | 2012-08-14 | Nodality, Inc. | Kits for multiparametric phospho analysis |
TW201117824A (en) | 2009-10-12 | 2011-06-01 | Amgen Inc | Use of IL-17 receptor a antigen binding proteins |
UA109888C2 (uk) | 2009-12-07 | 2015-10-26 | ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ | |
JP2013523184A (ja) | 2010-04-15 | 2013-06-17 | アムジエン・インコーポレーテツド | ヒトFGF受容体およびβ−KLOTHO結合性タンパク質 |
EP2564200B8 (en) | 2010-04-27 | 2019-10-02 | The Regents of The University of California | Cancer biomarkers and methods of use thereof |
EP2580329B1 (en) * | 2010-06-10 | 2018-07-11 | Active Motif, Inc. | Modified renilla luciferase nucleic acids and methods of use |
WO2012030738A2 (en) | 2010-08-30 | 2012-03-08 | Beckman Coulter, Inc. | Complex phosphoprotein activation profiles |
CN106290159A (zh) | 2011-01-21 | 2017-01-04 | 提拉诺斯公司 | 样品使用最大化的系统和方法 |
WO2012155071A1 (en) | 2011-05-12 | 2012-11-15 | Gilead Biologics, Inc. | Methods of identifying lysyl oxidase - like - 2 (loxl2) binding partners |
US9574002B2 (en) | 2011-06-06 | 2017-02-21 | Amgen Inc. | Human antigen binding proteins that bind to a complex comprising β-Klotho and an FGF receptor |
WO2013016220A1 (en) | 2011-07-22 | 2013-01-31 | Amgen Inc. | Il-17 receptor a is required for il-17c biology |
US20140170735A1 (en) | 2011-09-25 | 2014-06-19 | Elizabeth A. Holmes | Systems and methods for multi-analysis |
US9268915B2 (en) | 2011-09-25 | 2016-02-23 | Theranos, Inc. | Systems and methods for diagnosis or treatment |
US8840838B2 (en) | 2011-09-25 | 2014-09-23 | Theranos, Inc. | Centrifuge configurations |
US8435738B2 (en) | 2011-09-25 | 2013-05-07 | Theranos, Inc. | Systems and methods for multi-analysis |
US8475739B2 (en) | 2011-09-25 | 2013-07-02 | Theranos, Inc. | Systems and methods for fluid handling |
US9619627B2 (en) | 2011-09-25 | 2017-04-11 | Theranos, Inc. | Systems and methods for collecting and transmitting assay results |
US9632102B2 (en) | 2011-09-25 | 2017-04-25 | Theranos, Inc. | Systems and methods for multi-purpose analysis |
US9664702B2 (en) | 2011-09-25 | 2017-05-30 | Theranos, Inc. | Fluid handling apparatus and configurations |
ES2806146T3 (es) | 2011-09-22 | 2021-02-16 | Amgen Inc | Proteínas de unión al antígeno CD27L |
US9250229B2 (en) | 2011-09-25 | 2016-02-02 | Theranos, Inc. | Systems and methods for multi-analysis |
US10012664B2 (en) | 2011-09-25 | 2018-07-03 | Theranos Ip Company, Llc | Systems and methods for fluid and component handling |
US9810704B2 (en) | 2013-02-18 | 2017-11-07 | Theranos, Inc. | Systems and methods for multi-analysis |
CN104220460A (zh) | 2011-12-08 | 2014-12-17 | 安姆根有限公司 | 激动人lcat抗原结合蛋白和它们在疗法中的用途 |
AR091069A1 (es) | 2012-05-18 | 2014-12-30 | Amgen Inc | Proteinas de union a antigeno dirigidas contra el receptor st2 |
WO2014028939A2 (en) | 2012-08-17 | 2014-02-20 | California Institute Of Technology | Targeting phosphofructokinase and its glycosylation form for cancer |
TW201425336A (zh) | 2012-12-07 | 2014-07-01 | Amgen Inc | Bcma抗原結合蛋白質 |
ES2728936T3 (es) | 2013-01-25 | 2019-10-29 | Amgen Inc | Anticuerpos dirigidos contra CDH19 para melanoma |
JO3519B1 (ar) | 2013-01-25 | 2020-07-05 | Amgen Inc | تركيبات أجسام مضادة لأجل cdh19 و cd3 |
AU2014244444A1 (en) | 2013-03-14 | 2015-09-24 | Amgen Inc. | CHRDL-1 antigen binding proteins and methods of treatment |
HUE045859T2 (hu) | 2013-03-15 | 2020-01-28 | Amgen Res Munich Gmbh | N-terminális ABP-t tartalmazó, egyláncú kötõmolekulák |
WO2014144553A1 (en) | 2013-03-15 | 2014-09-18 | Amgen Inc. | Secreted frizzle-related protein 5 (sfrp5) binding proteins and methods of treatment |
EP2970446A1 (en) | 2013-03-15 | 2016-01-20 | Amgen Research (Munich) GmbH | Antibody constructs for influenza m2 and cd3 |
AU2014228924B2 (en) | 2013-03-15 | 2019-04-18 | Amgen Inc. | Human PAC1 antibodies |
CN110511279B (zh) | 2013-05-30 | 2024-03-29 | 基尼克萨制药有限公司 | 制瘤素m受体抗原结合蛋白 |
US10227370B2 (en) | 2013-08-02 | 2019-03-12 | California Institute Of Technology | Heparan sulfate/heparin mimetics with anti-chemokine and anti-inflammatory activity |
US9770461B2 (en) | 2013-08-02 | 2017-09-26 | California Institute Of Technology | Tailored glycopolymers as anticoagulant heparin mimetics |
TW201605896A (zh) | 2013-08-30 | 2016-02-16 | 安美基股份有限公司 | Gitr抗原結合蛋白 |
AR097648A1 (es) | 2013-09-13 | 2016-04-06 | Amgen Inc | Combinación de factores epigenéticos y compuestos biespecíficos que tienen como diana cd33 y cd3 en el tratamiento de leucemia mieloide |
RU2019119857A (ru) | 2014-02-20 | 2019-07-12 | Аллерган, Инк. | Антитела к компоненту комплемента c5 |
WO2015130826A1 (en) | 2014-02-27 | 2015-09-03 | Allergan, Inc. | COMPLEMENT FACTOR Bb ANTIBODIES |
AU2015295242B2 (en) | 2014-07-31 | 2020-10-22 | Amgen Research (Munich) Gmbh | Bispecific single chain antibody construct with enhanced tissue distribution |
AR101669A1 (es) | 2014-07-31 | 2017-01-04 | Amgen Res (Munich) Gmbh | Constructos de anticuerpos para cdh19 y cd3 |
JP6749312B2 (ja) | 2014-07-31 | 2020-09-02 | アムゲン リサーチ (ミュンヘン) ゲーエムベーハーAMGEN Research(Munich)GmbH | 最適化された種間特異的二重特異性単鎖抗体コンストラクト |
WO2016040767A2 (en) | 2014-09-12 | 2016-03-17 | Amgen Inc. | Chrdl-1 epitopes and antibodies |
WO2016090323A1 (en) | 2014-12-05 | 2016-06-09 | Prelude, Inc. | Dcis recurrence and invasive breast cancer |
PT3283524T (pt) | 2015-04-17 | 2023-06-05 | Amgen Res Munich Gmbh | Construções de anticorpos biespecíficos para cdh3 e cd3 |
WO2016189118A1 (en) | 2015-05-28 | 2016-12-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods of prognosis and treatment of patients suffering from acute myeloid leukemia |
TWI829617B (zh) | 2015-07-31 | 2024-01-21 | 德商安美基研究(慕尼黑)公司 | Flt3及cd3抗體構築體 |
TWI717375B (zh) | 2015-07-31 | 2021-02-01 | 德商安美基研究(慕尼黑)公司 | Cd70及cd3抗體構築體 |
TWI796283B (zh) | 2015-07-31 | 2023-03-21 | 德商安美基研究(慕尼黑)公司 | Msln及cd3抗體構築體 |
TW202346349A (zh) | 2015-07-31 | 2023-12-01 | 德商安美基研究(慕尼黑)公司 | Dll3及cd3抗體構築體 |
TWI744242B (zh) | 2015-07-31 | 2021-11-01 | 德商安美基研究(慕尼黑)公司 | Egfrviii及cd3抗體構築體 |
PE20181327A1 (es) | 2015-12-23 | 2018-08-20 | Amgen Inc | Metodo para tratar o mejorar trastornos metabolicos con proteinas de union para el receptor peptidico inhibidor gastrico (gipr) en combinacion con agonistas de glp-1 |
JOP20170017B1 (ar) | 2016-01-25 | 2021-08-17 | Amgen Res Munich Gmbh | تركيب صيدلي يتضمن تركيبات جسم مضاد ثنائي الاختصاص |
MA43955B1 (fr) | 2016-02-03 | 2022-02-28 | Amgen Inc | Anticorps anti-bcma et anti-cd3 bispécifiques de format bite |
EA039859B1 (ru) | 2016-02-03 | 2022-03-21 | Эмджен Рисерч (Мюник) Гмбх | Биспецифические конструкты антител, связывающие egfrviii и cd3 |
KR20180101623A (ko) | 2016-02-03 | 2018-09-12 | 암젠 리서치 (뮌헨) 게엠베하 | Psma 및 cd3 이중특이성 t 세포 맞물림 항체 작제물 |
JOP20170091B1 (ar) | 2016-04-19 | 2021-08-17 | Amgen Res Munich Gmbh | إعطاء تركيبة ثنائية النوعية ترتبط بـ cd33 وcd3 للاستخدام في طريقة لعلاج اللوكيميا النخاعية |
CN110312808A (zh) | 2016-06-30 | 2019-10-08 | 拜欧亿思有限公司 | 双链核酸信号探针以及利用上述双链核酸信号探针的靶分子检测方法 |
JOP20190177A1 (ar) | 2017-01-17 | 2019-07-16 | Amgen Inc | طريقة لعلاج أو تحسين اضطرابات أيضية باستخدام مساعدات مستقبل glp-1 مقترنة بمناهضات لمستقبل ببتيد مثبط معوي (gipr) |
JOP20190189A1 (ar) | 2017-02-02 | 2019-08-01 | Amgen Res Munich Gmbh | تركيبة صيدلانية ذات درجة حموضة منخفضة تتضمن بنيات جسم مضاد يستهدف الخلية t |
AU2018220516A1 (en) | 2017-02-16 | 2019-09-19 | Sonnet BioTherapeutics, Inc. | Albumin binding domain fusion proteins |
SG11201909547TA (en) | 2017-05-05 | 2019-11-28 | Amgen Inc | Pharmaceutical composition comprising bispecific antibody constructs for improved storage and administration |
JOP20190259A1 (ar) | 2017-05-31 | 2019-10-31 | Amgen Inc | بروتينات ربط مولد ضد مضادة لـ jagged1 |
AR111842A1 (es) | 2017-06-02 | 2019-08-21 | Amgen Inc | Antagonistas de péptido pac1 |
CR20190532A (es) | 2017-06-20 | 2020-01-10 | Amgen Inc | Método para tratar o mejorar trastornos metabólicos con proteínas de unión para el receptor peptídico inhibidor gástrico (gipr) en combinación con agonistas de glp-1 |
EP3661562A1 (en) | 2017-08-04 | 2020-06-10 | Amgen Inc. | Method of conjugation of cys-mabs |
BR112020011627A2 (pt) | 2017-12-11 | 2020-11-17 | Amgen Inc. | processo de fabricação contínuo para produtos de anticorpos biespecíficos |
TW201940518A (zh) | 2017-12-29 | 2019-10-16 | 美商安進公司 | 針對muc17和cd3之雙特異性抗體構建體 |
US20210301017A1 (en) | 2018-07-30 | 2021-09-30 | Amgen Research (Munich) Gmbh | Prolonged administration of a bispecific antibody construct binding to cd33 and cd3 |
AU2019314999A1 (en) | 2018-08-03 | 2021-02-11 | Amgen Inc. | Antibody constructs for CLDN18.2 and CD3 |
EP3850368A4 (en) | 2018-09-14 | 2022-11-23 | Prelude Corporation | PROCEDURE FOR SELECTING THE TREATMENT OF SUBJECTS AT RISK FOR INVASIVE BREAST CANCER |
CN112703204A (zh) | 2018-09-28 | 2021-04-23 | 安进公司 | 针对可溶性bcma的抗体 |
SG11202103275YA (en) | 2018-10-11 | 2021-04-29 | Amgen Inc | Downstream processing of bispecific antibody constructs |
EP3877413A1 (en) | 2018-11-06 | 2021-09-15 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of acute myeloid leukemia by eradicating leukemic stem cells |
SG11202106478UA (en) | 2019-01-03 | 2021-07-29 | Invetx Inc | Compositions for increasing half-life of a therapeutic agent in canines and methods of use |
US20220259547A1 (en) | 2019-06-13 | 2022-08-18 | Amgeng Inc. | Automated biomass-based perfusion control in the manufacturing of biologics |
EP4028416A1 (en) | 2019-09-10 | 2022-07-20 | Amgen Inc. | Purification method for bispecific antigen-binding polypeptides with enhanced protein l capture dynamic binding capacity |
WO2021097344A1 (en) | 2019-11-13 | 2021-05-20 | Amgen Inc. | Method for reduced aggregate formation in downstream processing of bispecific antigen-binding molecules |
EP4093771A1 (en) | 2020-01-22 | 2022-11-30 | Amgen Research (Munich) GmbH | Combinations of antibody constructs and inhibitors of cytokine release syndrome and uses thereof |
WO2021188851A1 (en) | 2020-03-19 | 2021-09-23 | Amgen Inc. | Antibodies against mucin 17 and uses thereof |
JP2023526225A (ja) | 2020-05-11 | 2023-06-21 | インベテックス インコーポレイテッド | 治療薬のイヌにおける半減期を増加させるための組成物及びその使用方法 |
AU2021275049A1 (en) | 2020-05-19 | 2022-12-22 | Amgen Inc. | MAGEB2 binding constructs |
MX2022014902A (es) | 2020-05-29 | 2023-01-04 | Amgen Inc | Administracion mitigadora de efectos adversos de un constructo biespecifico que se une a cd33 y cd3. |
WO2022008488A1 (en) | 2020-07-06 | 2022-01-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of slamf1 as a biomarker in colorectal cancer |
WO2022010652A1 (en) | 2020-07-10 | 2022-01-13 | Invetx Inc. | Compositions for increasing half-life of a therapeutic agent in felines and methods of use |
WO2022013256A1 (en) | 2020-07-15 | 2022-01-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of cd160 as a biomarker in acute myeloid leukemia |
TW202233678A (zh) | 2020-11-06 | 2022-09-01 | 德商安美基研究(慕尼黑)公司 | 具有增強的剪切特徵的多肽 |
CA3199976A1 (en) | 2020-11-06 | 2022-05-12 | Amgen Research (Munich) Gmbh | Polypeptide constructs selectively binding to cldn6 and cd3 |
WO2022096698A1 (en) | 2020-11-06 | 2022-05-12 | Amgen Inc. | Polypeptide constructs binding to cd3 |
IL302599A (en) | 2020-11-06 | 2023-07-01 | Amgen Inc | Bispecific molecules bind multi-target antigens of increased selectivity |
CA3203106A1 (en) | 2021-01-20 | 2022-07-28 | Parag Mallick | Systems and methods for biomolecule quantitation |
AR125290A1 (es) | 2021-04-02 | 2023-07-05 | Amgen Inc | Construcciones de unión a mageb2 |
WO2022234102A1 (en) | 2021-05-06 | 2022-11-10 | Amgen Research (Munich) Gmbh | Cd20 and cd22 targeting antigen-binding molecules for use in proliferative diseases |
TW202346368A (zh) | 2022-05-12 | 2023-12-01 | 德商安美基研究(慕尼黑)公司 | 具有增加的選擇性的多鏈多靶向性雙特異性抗原結合分子 |
WO2024059675A2 (en) | 2022-09-14 | 2024-03-21 | Amgen Inc. | Bispecific molecule stabilizing composition |
WO2024104551A1 (en) | 2022-11-14 | 2024-05-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of the population of slamf4+ ccr5+ effector memory cd4+ t cells as a biomarker in rheumatoid arthritis |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0247193A1 (en) * | 1985-12-02 | 1987-12-02 | The Regents Of The University Of California | Isolation of dna sequences encoding luciferase activity and applications of the same |
US4983511A (en) * | 1989-01-09 | 1991-01-08 | Olin Corporation | Method and kit for detecting live microorganisms in chlorine- or bromine-treated water |
US4956190A (en) * | 1989-04-24 | 1990-09-11 | Borden, Inc. | Tempering and milling of edible grains and leguminous materials with reducing agents and methods of making alimentary products |
-
1991
- 1991-03-11 JP JP03506544A patent/JP3126980B2/ja not_active Expired - Lifetime
- 1991-03-11 DK DK91908378T patent/DK0575319T3/da active
- 1991-03-11 EP EP91908378A patent/EP0575319B1/en not_active Expired - Lifetime
- 1991-03-11 DE DE69131780T patent/DE69131780T2/de not_active Expired - Lifetime
- 1991-03-11 ES ES91908378T patent/ES2142801T3/es not_active Expired - Lifetime
- 1991-03-11 WO PCT/US1991/001614 patent/WO1992015673A1/en active IP Right Grant
- 1991-03-11 CA CA002105984A patent/CA2105984C/en not_active Expired - Lifetime
-
2000
- 2000-02-09 GR GR20000400307T patent/GR3032608T3/el not_active IP Right Cessation
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002507410A (ja) * | 1998-03-27 | 2002-03-12 | プロルーム・リミテッド | ルシフェラーゼ、蛍光タンパク質、ルシフェラーゼおよび蛍光タンパク質をコードする核酸および、診断、高処理スクリーニングおよび新規アイテムにおけるその使用 |
Also Published As
Publication number | Publication date |
---|---|
ES2142801T3 (es) | 2000-05-01 |
WO1992015673A1 (en) | 1992-09-17 |
EP0575319A1 (en) | 1993-12-29 |
DE69131780T2 (de) | 2000-11-16 |
DE69131780D1 (de) | 1999-12-16 |
CA2105984A1 (en) | 1992-09-12 |
EP0575319A4 (en) | 1995-04-26 |
DK0575319T3 (da) | 2000-07-10 |
CA2105984C (en) | 2002-11-26 |
EP0575319B1 (en) | 1999-11-10 |
JP3126980B2 (ja) | 2001-01-22 |
GR3032608T3 (en) | 2000-05-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH06504903A (ja) | レニラ(renilla)ルシフェラーゼのクローニング及び発現 | |
US5292658A (en) | Cloning and expressions of Renilla luciferase | |
AU730040B2 (en) | Renilla luciferase and green fluorescent protein fusion genes | |
JP5295206B2 (ja) | ルシフェラーゼ発現カセットおよび使用法 | |
JP5781789B2 (ja) | ルシフェラーゼバイオセンサー | |
JP4999341B2 (ja) | 変異型ホタルルシフェラーゼ、遺伝子、組換えベクター、形質転換体、及び変異型ホタルルシフェラーゼの製造方法 | |
JP4519163B2 (ja) | 単離されたルシフェラーゼおよびその使用 | |
CA2387691A1 (en) | Novel enzyme | |
EP3778650A1 (en) | Fluorescent probe for branched chain amino acids and use thereof | |
JP2011083289A (ja) | 変異型ルシフェラーゼ | |
JP2003509029A5 (ja) | ||
JP2020505028A (ja) | 新規ルシフェラーゼおよびその使用方法 | |
US20120034634A1 (en) | Modified luciola cruciata luciferase protein | |
CN114507654A (zh) | 新型Cas酶和系统以及应用 | |
CN111269324A (zh) | 高斯荧光素酶和地高辛单链抗体的融合蛋白及其应用 | |
JPH05244942A (ja) | 耐熱性ホタルルシフェラーゼ、耐熱性ホタルルシフェラーゼ遺伝子、新規な組み換え体dna、及び耐熱性ホタルルシフェラーゼの製造法 | |
EP1468284B1 (en) | Method for measuring intracellular atp and/or gene expression | |
AU2002339151A1 (en) | Method for measuring intracellular ATP and/or gene expression | |
WO2024000408A1 (zh) | 荧光素酶突变体及其应用 | |
ZA200403508B (en) | Signal system and elements used therein | |
CN115261363A (zh) | Apobec3a的rna脱氨酶活性测定方法及rna高活性的apobec3a变体 | |
JP5589369B2 (ja) | 変異ガウシアルシフェラーゼ | |
CN111117978A (zh) | 一种单链DNA肽连接酶sDPlaseI及其使用方法 | |
JPH10150991A (ja) | ルシフェラーゼ−リゾスタフィン融合タンパク質、その製造法及びそれを用いた生物発光分析法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20081102 Year of fee payment: 8 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20091102 Year of fee payment: 9 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20091102 Year of fee payment: 9 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101102 Year of fee payment: 10 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111102 Year of fee payment: 11 |
|
EXPY | Cancellation because of completion of term | ||
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111102 Year of fee payment: 11 |